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Abstract
The increasing emergence of multidrug-resistant bacteria is recognized as a major threat to
human health worldwide. While the use of small molecule antibiotics has enabled
many modern medical advances, it has also facilitated the development of resistant organ-
isms. This minireview provides an overview of current small molecule drugs approved
by the US Food and Drug Administration (FDA) for use in humans, the unintended conse-
quences of antibiotic use, and the mechanisms that underlie the development of
drug resistance. Promising new approaches and strategies to counter antibiotic-resistant
bacteria with small molecules are highlighted. However, continued public investment in this
area is critical to maintain an edge in our evolutionary “arms race” against antibiotic-
resistant microorganisms.
Keywords: Bacteria, drugs, mechanisms, pharmacology, resistance, small molecule inhibitors
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Introduction
Antibiotic-resistant bacteria are a major public health con-
cern, and the treatment of drug-resistant infections is
increasingly problematic. More than 150 small molecule
drugs have been approved by the US Food and Drug
Administration (FDA) over eight decades for the treatment
of bacterial infections. In the context of this article, we will
define a “small molecule” based on the FDA’s assessment
of a drug substance as a “chemical” according to ISO IDMP
11238.1 Additionally, we include mixtures, as specified by
the FDA, provided that each component of the mixture is
classified as a “chemical”. Both the misuse and overuse of
antibiotics have been cited as the major driving forces for
the development of resistance among human pathogens.
Globalization and international travel increases the likeli-
hood that an easily-transmissible antibiotic-resistant infec-
tion could result in a pandemic. The lack of effective
antibiotic therapies jeopardizes many modern medical
practices including transplantation, cancer chemotherapy,
surgeries, and care of the critically ill or premature infants.2
Understanding the mechanisms of antibiotic resistance is
critical for developing new and innovative approaches for
Impact statement
The alarming increase in antibiotic-
resistant microorganisms is a rapidly
emerging threat to human health through-
out the world. Historically, small molecule
drugs have played a major role in control-
ling bacterial infections and they continue
to offer tremendous potential in countering
resistant organisms. This minireview pro-
vides a broad overview of the relevant
issues, including the diversity of FDA-
approved small molecule drugs and
mechanisms of drug resistance, unin-
tended consequences of antibiotic use, the
current state of development for small
molecule antibacterials and financial chal-
lenges that impact progress towards novel
therapies. The content will be informative
to diverse stakeholders, including clini-
cians, basic scientists, translational scien-
tists and policy makers, and may be used
as a bridge between these key players to
advance the development of much-needed
therapeutics.
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better and more effective treatments.3–5 This article pro-
vides some context and reviews the recent literature
describing the development of small molecule therapies
to circumvent antibiotic resistance.
US Food and Drug Administration-approved
small molecule antibacterial drugs and their
targets
Many antibacterial drugs are natural products that were
isolated from microbes in the soil.6 Therefore, elucidating
the antimicrobial mechanisms of action has been a subject
of intense interest, and numerous investigations have led to
the categorization of these drugs by their effects on the bac-
terial cell. The vast majority of antibiotics target the disrup-
tion of either the bacterial cell wall or membrane, or
interfere with essential processes involved in metabolism
and replication (Figure 1). While the mechanisms of action
for many antibiotics have been described, there are still
classes of antimicrobials for which specific binding sites
or target(s) remain unknown. These systems continue to
be scrutinized for insight into potential areas of exploitation
for promising drugs. Studies suggest that the activities of
antibacterial drugs are extended beyond the initial drug/
target interaction to metabolic and homeostatic networks so
that the efficacy of a drug depends on its mode of action in a
given cellular context.7 Table 1 lists the small molecule anti-
biotics approved by the FDA alongwith the approval years.
Figure 2 shows the number of small molecule antibacterial
drugs approved for human use between 1939 and 2017
grouped according to the antibiotic class.
Cell wall synthesis
Peptidoglycan provides the bacterial cell with its funda-
mental structural integrity and essential reactions can be
inhibited when antibiotics bind to penicillin binding pro-
teins (PBPs) that are crucial for forming peptidoglycan.
Upon the arrest of peptidoglycan production, the cell wall
loses its integrity, causing lysis of the bacterium.8
Antibiotics that include the b-lactams and glycopeptides
are effective against bacteria due to their ability to interfere
with bacterial peptidoglycan synthesis.9 Subclasses of
the b-lactams include penicillins, cephalosporins, mono-
bactams, carbapenems, and clavams. Vancomycin is a gly-
copeptide class antibiotic that has been FDA-approved.
Peptidoglycan synthesis is also inhibited by the oxazolidi-
none class antibiotic cycloserine and the polypeptide class
antibiotic bacitracin.
Cell membrane function
The lipopeptide class antibioticdaptomycin targets the cell
wall in Gram-positive microorganisms. While the exact
mechanism responsible for the membrane disruption
remains unknown, it has been shown that the presence of
both phosphatidylglycerol (PG) and calcium are necessary
for daptomycin to be effective. Comparisons among mem-
branes that contain PG and those made entirely of phos-
phatidylcholine have shown that daptomycin is less
effective on membranes without PG. Calcium levels are
also important, as the concentration of daptomycin
needed to penetrate the cell membrane decreases by as
much as 50-fold in the presence of calcium ions.10 The poly-
peptide class antibiotic polymyxin B is active against Gram-
negative organisms, destabilizing both the outer and inner
membranes.11
Protein synthesis
Several classes of antibiotics target ribosomes in order to
disrupt protein synthesis in bacteria. These classes of anti-
biotics include the phenicols, macrolides, lincosamides,
and streptogramins which bind to the 50S ribosomal sub-
unit and hinder translation. It is thought that the structures
of lincosamides might resemble the 30-ends of L-Pro-Met-
tRNA and deacylated-tRNA, allowing them to bind to and
subsequently inhibit the ribosome.12 The oxazolidinone
class antibiotics linezolid and tedizolid also inhibit protein
synthesis by binding the 50S ribosomal subunit.
In the bacterial ribosome, the 30S subunit is a target for
other classes of antibiotics such as the tetracyclines and
aminoglycosides. Examples of aminoglycosides include
kanamycin, gentamicin, neomycin, and streptomycin.
These drugs bind to the 16S ribosomal RNA within the
30S subunit and do not allow the binding of charged
aminoacyl-tRNA to the ribosome, thereby arresting protein
synthesis. While the exact site of tetracycline binding has
yet to be identified, a recent study suggested that the ribo-
somal RNA structure is more important than the actual
ribonucleotide sequence for binding, as tetracyclines can
bind to random sequences of double-stranded RNA.13
Nucleic acid synthesis
Bacterial enzymes are targets of antibiotics, including those
that play roles in nucleic acid synthesis, DNA replication
and regulation. Sulfonamide drugs were the first class to be
FDA-approved beginning in 1939 and act as competitive
inhibitors of the enzyme dihydropteroate synthase, which
is required for the synthesis of tetrahydrofolic acid and
nucleotides. The diaminopyrimidine trimethoprim targets
the same pathway by inhibiting dihydrofolate reductase.
Enzymes like DNA gyrase, type IIA topoisomerases, and
topoisomerase IV serve as targets of the quinolone class of
antibiotics. Topoisomerases form covalent bonds with
DNA and catalyze DNA breakage and re-ligation. The qui-
nolones inhibit these topoisomerases, resulting in the for-
mation of ternary complexes that cause strand breakage
and block DNA re-ligation. Quinolones were also shown
to lower the threshold of magnesium ions required for top-
oisomerases to initiate strand breakage, allowing for
increased rates of cleavage and the formation of ternary
complexes.14 The rifamycin class of antibiotics inhibit
RNA polymerase and prevent RNA synthesis.15
Recent FDA approvals
There were no new approvals of small molecule antibacte-
rial drugs by the FDA in 2016; however, three were
approved in 2017 as of 10 October 2017. Secnidazole
(Symbiomix Therapeutics, approved 15 September 2017)
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is a nitroimidazole antibiotic reported as early as 1976,
but only now approved for bacterial vaginosis in adult
women.16 Also, a combination of the broad-spectrum
b-lactam antibiotic meropenem with the new b-lactamase
inhibitor vaborbactam (trade name Vabomere, Rempex
Pharmaceuticals, approved 29 August 2017) was approved
as an injection formulation for treating complicated urinary
tract infections. Vaborbactam is a new chemotype
containing a boronic acid that covalently inhibits serine-
containing carbapenemases at the active site.17 While
vaborbactam inhibits by a new mechanism of action, it
does not act against a new target class and it is an adjuvant
to the antibiotic. Finally, delafloxacin is a fluoroquinoline
(Melinta Therapeutics, approved 19 June 2017) used to treat
patients with acute bacterial skin and skin structure infec-
tions (ABSSSI).18
Figure 1. Anatomy of Gram-negative and Gram-positive bacteria and their susceptibility to antibiotics. (a) The cell wall of Gram-negative bacteria includes outer and
inner (cytoplasmic) membranes, which form the barriers of the periplasmic space that contains a thin layer of peptidoglycan. The outer leaflet of the outer membrane
contains lipopolysaccharide (LPS) consisting of lipid A and O-polysaccharide. The outer membrane contains porins, which provide entrance to the periplasm for some
molecules. (b) The outer wall of Gram-positive bacteria contains a thick layer of peptidoglycan that retains the crystal violet stain used in the Gram stain test. Teichoic
acids, which are not found in Gram-negative bacteria, are called lipoteichoic acids (LTA) when anchored to the cytoplasmic membrane. Gram-positive bacteria lack an
outer membrane and thus are more susceptible to antibiotics. Both Gram-negative and Gram-positive cell walls contain efflux pumps and other active pumps that can
export intracellular molecules, including antibiotics. (c) Gram-negative bacteria are intrinsically resistant to many antibiotics due to the architecture of their cell walls.
Nevertheless, a variety of antibiotics are effective by targeting the synthesis of protein, the cell wall or nucleic acids. Resistance to antibiotics can be mediated by
increased efflux by pumps and reduced permeability through porins in addition to other mechanisms, including target mutation, overexpression or protection and drug
inactivation.
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Table 1. Small molecule antibacterials approved by the US Food and Drug Administration (FDA) for use in humans.a
Type Class Drug
FDA-Approval
Year Figure 3 ID
MCS
Cluster
ISO 11238
Substance Type
Molecular Weight or
Weight Range (Daltons)
ß-Lactams
Penicillins
Penicillin G 1947 1 2 chemical 334.39
Penicillin V 1954 2 2 chemical 350.39
Pheneticillin 1959 3 2 chemical 364.42
Methicillin 1960 4 2 chemical 380.42
Oxacillin 1962 5 1 chemical 401.44
Ampicillin 1963 6 2 chemical 349.41
Nafcillin 1964 7 2 chemical 414.48
Cloxacillin 1965 8 1 chemical 435.88
Dicloxacillin 1968 10 1 chemical 470.33
Carbenicillin 1972 13 2 chemical 378.40
Amoxicillin 1974 15 2 chemical 365.40
Ticarcillin 1976 19 2 chemical 384.43
Bacampicillin 1980 24 5 chemical 465.52
Mezlocillin 1981 26 2 chemical 539.58
Piperacillin 1981 27 2 chemical 517.56
Amdinocillin 1984 32 0 chemical 325.43
Sulbactam 1986 41 11 chemical 233.24
Cephalosporins
Cephaloridine 1968 9 0 chemical 415.49
Cephaloglycin 1970 11 5 chemical 405.43
Cephalexin 1971 12 5 chemical 347.39
Cefazolin 1973 14 8 chemical 454.51
Cephalothin 1974 16 8 chemical 396.44
Cephradine 1974 17 8 chemical 349.41
Cephapirin 1974 18 8 chemical 423.46
Cefadroxil 1978 20 5 chemical 363.39
Cefamandole 1978 21 6 chemical 462.50
Cefoxitin 1978 22 10 chemical 427.45
Cefaclor 1979 23 5 chemical 367.81
Latamoxef 1981 25 0 chemical 520.47
Cefotaxime 1981 28 3 chemical 455.47
Cefoperazone 1982 29 5 chemical 645.67
Ceftizoxime 1983 30 3 chemical 383.40
Cefuroxime 1983 31 10 chemical 424.39
Cefonicid 1984 35 7 chemical 542.57
Ceforanide 1984 36 7 chemical 519.55
Ceftriaxone 1984 34 3 chemical 554.58
Ceftazidime 1985 38 3 chemical 545.57
Cefotetan 1985 39 7 chemical 575.62
Cefmenoxime 1987 42 3 chemical 511.56
Cefotiam 1988 43 6 chemical 525.63
Cefpiramide 1989 45 5 chemical 612.64
Cefixime 1989 44 3 chemical 453.45
Cefmetazole 1989 46 7 chemical 471.53
Cefprozil 1991 48 5 mixture 389.43
Loracarbef 1991 47 5 chemical 349.77
Cefpodoxime 1992 49 4 chemical 427.46
Tazobactam 1993 50 11 chemical 300.29
Ceftibuten 1995 51 0 chemical 410.43
Cefepime 1996 52 3 chemical 480.56
Cefdinir 1997 54 3 chemical 395.41
Cefditoren 2001 55 3 chemical 506.58
Ceftaroline fosamil 2010 58 0 chemical 684.69
Ceftolozane 2014 59 4 chemical 666.69
Monobactams
Aztreonam 1986 40 0 chemical 435.43
Carbapenems
Imipenem 1985 37 0 chemical 299.35
Meropenem 1996 53 9 chemical 383.46
Ertapenem 2001 56 9 chemical 475.52
Doripenem 2007 57 9 chemical 420.50
(continued)
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Table 1. Continued
Type Class Drug
FDA-Approval
Year Figure 3 ID
MCS
Cluster
ISO 11238
Substance Type
Molecular Weight or
Weight Range (Daltons)
Clavams
Clavulanic acid 1984 33 0 chemical 199.16
MLS family
Lincosamides
Lincomycin 1964 chemical 406.54
Clindamycin 1970 chemical 424.98
Macrolides
Erythromycin 1952 chemical 733.93
Troleandomycin 1956 chemical 813.97
Clarithromycin 1991 chemical 747.95
Azithromycin 1991 chemical 748.98
Dirithromycin 1995 chemical 835.07
Telithromycin 2004 chemical 812.00
Streptogramins
Quinupristin 1999 chemical 1022.22
Dalfopristin 1999 chemical 690.85
Other Antibiotics
Acylampicillin
Azlocillin 1982 chemical 461.49
Aminocyclitol
Spectinomycin 1971 chemical 332.35
Aminoglycosides
Streptomycin 1946 chemical 581.57
Neomycin 1951 mixture 322.36 – 614.64
Paromomycin 1960 chemical 615.63
Gentamicin 1966 mixture 449.54 – 477.60
Tobramycin 1975 chemical 467.51
Amikacin 1976 chemical 585.60
Kanamycin 1981 mixture 483.51 – 484.50
Netilmicin 1983 chemical 475.58
Aminosalicylates
Aminosalicylic acid 1948 chemical 153.14
Diaminopyrimidines
Trimethoprim 1973 chemical 290.32
Diarylquinolines
Bedaquiline 2012 chemical 555.51
Glycopeptides
Vancomycin 1958 chemical 1449.25
Glycylcyclines
Tigecycline 2005 chemical 585.65
Isonicotinic acid
Isoniazid 1952 chemical 137.14
Lipoglycopeptides
Telavancin 2009 chemical 1755.64
Oritavancin 2014 chemical 1793.10
Dalbavancin 2014 mixture 1802.67 – 1830.72
Oritavancin 2014 chemical 1793.10
Lipopeptides
Daptomycin 2003 chemical 1620.67
Macrocyclics
Fidaxomicin 2011 chemical 1058.04
Monoxycarbolic acids
Mupirocin 1987 chemical 500.62
N-substituted ethylenediamine
Ethambutol 1967 chemical 204.31
Nicotinamide derivative
Ethionamide 1965 chemical 166.24
Nitrofurans
Nitrofurantoin 1953 chemical 238.16
Furazolidone 1955 chemical 225.16
(continued)
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Table 1. Continued
Type Class Drug
FDA-Approval
Year Figure 3 ID
MCS
Cluster
ISO 11238
Substance Type
Molecular Weight or
Weight Range (Daltons)
Nitroimidazoles
Metronidazole 1963 chemical 171.15
Tinidazole 2004 chemical 247.27
Secnidazole 2017 chemical 185.18
Non--lactam -lactamase inhibitors
Avibactam 2015 chemical 265.24
Vaborbactam 2017 chemical 297.14
Oxazolidinones
Cycloserine 1964 chemical 102.09
Linezolid 2000 chemical 337.35
Tedizolid 2014 chemical 370.34
Phenicols
Chloramphenicol 1949 chemical 323.13
Phosphonic acid derivative
Fosfomycin 1996 chemical 138.06
Pleuromutilins
Retapamulin 2007 chemical 517.76
Polymyxins
Colistin 1959 mixture 1155.43 – 1169.46
Polypeptides
Bacitracin 1948 mixture 1408.67 – 1422.69
Polymyxin B 1951 mixture 1189.45 – 1203.48
Pyrazines
Pyrazinamide 1955 chemical 123.11
Quinolones
Nalidixic acid 1964 chemical 232.24
Oxolinic acid 1975 chemical 261.23
Norfloxacin 1986 chemical 319.33
Ciprofloxacin 1987 chemical 331.34
Ofloxacin 1990 chemical 361.37
Enoxacin 1991 chemical 320.32
Lomefloxacin 1992 chemical 351.35
Sparfloxacin 1996 chemical 392.40
Levofloxacin 1996 chemical 361.37
Grepafloxacin 1997 chemical 359.39
Trovafloxacin 1997 chemical 416.35
Moxifloxacin 1999 chemical 401.43
Gatifloxacin 2003 chemical 375.39
Gemifloxacin 2003 chemical 389.38
Besifloxacin 2009 chemical 393.84
Finafloxacin 2014 chemical 398.39
Delafloxacin 2017 chemical 440.76
Rifamycins
Rifampin 1971 chemical 822.94
Rifabutin 1992 chemical 847.00
Rifapentine 1998 chemical 877.03
Rifaximin 2004 chemical 785.88
Riminophenazine
Clofazimine 1986 chemical 473.40
Sulfonamides
Sulfapyridine 1939 chemical 249.29
Sulfadiazine 1941 chemical 250.28
Sulfamerazine 1943 chemical 264.30
Sulfathiazole 1945 chemical 255.32
Sulfacetamide 1945 chemical 214.24
Sulfoxone 1947 chemical 404.48
Sulfisoxazole 1949 chemical 267.30
Sulfamethizole 1953 chemical 270.33
Sulfamethoxazole 1961 chemical 253.28
(continued)
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Unintended consequences of antibiotic use
Alexander Fleming’s discovery of penicillin in 1928 and its
release for use in 1942 marked the era of antibiotics and the
foundation for the treatment of diseases that had
previously been lethal, such as staphylococcal and strepto-
coccal infections.19 However, over the last several decades
we have seen an overwhelming increase in resistance to
various antimicrobials. Further, there are a number of
undesirable outcomes that occur during and after antibiotic
Table 1. Continued
Type Class Drug
FDA-Approval
Year Figure 3 ID
MCS
Cluster
ISO 11238
Substance Type
Molecular Weight or
Weight Range (Daltons)
Sulfanilamide 1965 chemical 172.21
Mafenide 1969 chemical 186.23
Sulfaphenazole 1974 chemical 314.36
Sulfadoxine 1981 chemical 310.33
Sulfones
Dapsone 1957 chemical 248.30
Tetracyclines
Chlortetracycline 1950 chemical 478.88
Oxytetracycline 1950 chemical 460.43
Tetracycline 1953 chemical 444.43
Demeclocycline 1960 chemical 464.85
Methacycline 1966 chemical 442.42
Doxycycline 1967 chemical 444.43
Minocycline 1971 chemical 457.48
Triazinanes
Methenamine 1967 chemical 140.19
Tuberactinomycins
Viomycin 1953 chemical 685.69
Capreomycin 1971 mixture 524.53 – 668.71
aThe table is organized according to antibiotic type, class, drug name, FDA-approval year, identification number in Figure 3 and MCS cluster designation (b-lactam
drugs only), ISO 11238 substance type, and molecular weight or weight range (for mixtures). The maximal common substructure (MSC) clustering analysis was
performed with b-lactam drugs as described in the Figure 3 legend and all b-lactams were assigned as either singletons (designated as zero) or one of eleven MCS
clusters as indicated in the table. The list of antibacterial drugs was constructed from the NCATS Inxight Drugs database (https://drugs.ncats.io) and eMedExpert
(http://www.emedexpert.com/lists/antibiotics.shtml#1) followed by manual curation. Both FDA drug approval databases, Drugs@FDA and the FDA Orange Book,
were used to confirm each approval status and date. Effort was made to exclude salts, esters and known pro-drug variants of other approved antibiotic substances.
For any active moiety not associated with a definite approval date from FDA’s databases, the approval date from the NCATS Inxight Drugs resource was used.
Figure 2. Small molecule antibacterial drugs approved by the US Food and Drug Administration (FDA) for use in humans. This plot shows the number of drugs
approved within five-year periods from 1939 until 2017 (all drugs are listed in Table 1). The 157 drugs are grouped according to 20 classifications as shown by the
legend. The greatest number of drugs were approved between 1981 and 1985, consisting of 19 antibacterials that span more than six classifications. During the past
three decades, the number of approved small molecule antibacterial drugs has steadily decreased.
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treatment that can exacerbate the duration and severity of
infectious diseases.
Alteration of the microbiome
The human microbiome plays a vital role in host health.
It is comprised of trillions of microbial cells encompassing
as many as 500 species,20,21 maintains a crucial symbiotic
relationship with the host and plays a fundamental role in
educating the immune system.22 The components of one’s
own microbiota are unique enough to be used for self-
identification, and success in using the community struc-
ture of the human gut to distinguish individuals in a group
has been demonstrated.23 The commensal bacteria of
the human microbiota maintain over two orders of magni-
tude more genes than their host,24 including those that
encode enzymes that facilitate host digestion, lipid
absorption via bile acid conversion, vitamin production
as well as the protection and maintenance of the intestinal
mucosa.25–28 Along with providing essential functions to
the host, commensals also compete with pathogenic micro-
organisms for nutrition and attachment sites and therefore
help prevent infection. Bohnhoff andMiller first reported in
1962 what is now known as “colonization resistance” by
determining that mice were significantly more susceptible
to Salmonella infection after treatment with streptomycin,
which decreased the normal gut microbiota.29 Antibiotic
treatment eliminates many commensal organisms in the
gut, enabling enteric pathogens such as Clostridium difcile,
vancomycin-resistant Enterococcus faecalis, and Salmonella
enterica serovar Typhimurium to colonize and infect the
host.30–32 Antibiotic-mediated disruption of the normal
microbiota has also been implicated in liver disease and
colorectal cancers.33–35 Further, these changes in the gut
flora can lead to significantly elevated levels of resistance
genes in the microbial population, the increased carriage of
which might last for many years following a single course
of antibiotic treatment.36 Changes in the microbiota of the
upper respiratory tract, skin and genitourinary tract can
likewise affect susceptibility to infections. A recent system-
atic review of the potential for exposure to antibiotics to
increase the risk of community-acquired infections found
that the collateral damage to the patient’s microbiome
could be associated with upper respiratory, urinary tract
and soft tissue infections as well as infectious diarrhea,
and that this association decreased with increasing time
since antibiotic exposure.37
Activation of toxin–antitoxin systems
Another consequence of antibiotic use is the induction of
growth arrest in bacteria subsequent to the activation of
toxin–antitoxin (TA) modules. Five unique TA families
have been identified (I-V); the toxin is always a protein
but the antitoxin can be a protein or nucleic acid, and this
characteristic determines to which family a module
belongs. These gene pairs are found in hundreds of bacteria
as well as in the archaea.38 The type II TA systems have
protein antitoxins and are the best characterized. Upon
translation, the toxin and antitoxin interact to form a non-
toxic complex. When bacteria experience stress in their
microenvironment, such as exposure to reactive oxidative
species, nutrient limitation, temperature, pH or pressure
changes and antibiotic therapy, induced proteases such
as Lon and ClpXP degrade the labile antitoxin, freeing the
more stable toxin to carry out its function.39,40 In the type II
TA modules, the toxin is often a ribonuclease enzyme
which when released from its cognate antitoxin cleaves bac-
terial mRNA, eliciting a state of reversible growth arrest.
It is thought that many bacterial species in the environment
have maintained these systems to enhance their ability to
survive nutrient-poor and harsh conditions over hundreds
(and, in some cases, thousands) of years.41 For bacterial
pathogens, this state of stasis results in nonspecific toler-
ance to antimicrobials that target enzymes and pathways
essential to growth and replication, allowing a subpopula-
tion to survive antibiotic therapy and resume growth later
when conditions improve.
Livestock use generating resistance
Antimicrobial resistance is a problem in veterinary medi-
cine and the inappropriate use of these agents in agricul-
ture continues to have a significant impact on human
health. Antibiotics are routinely used in animal production
to promote growth by preventing and treating infections.42
The preventative treatment of entire flocks or herds over
time has facilitated the evolution of increased numbers
of resistant pathogens. For example, there has been a
marked rise in multidrug-resistant (MDR) Escherichia coli,
Salmonella, Campylobacter, and methicillin-resistant
Staphylococcus aureus (MRSA) emerging from commercial
animal production across the globe.43–45 In 2014, approxi-
mately 9.7 million kilograms of medically-important anti-
biotics were sold for use in food-producing animals in the
United States (including almost 7 million kilograms of the
tetracycline drug class alone), compared with approximate-
ly 3.5 million kilograms of antibiotics sold for human use.46
On large farms with poor living conditions, livestock are
treated with high doses of various antibiotics to decrease
disease until slaughter. This practice selects for resistant
bacteria which can be spread to packaging plants and
end up in the kitchens of consumers.47 Improper cooking
and poor hand hygiene can facilitate dissemination, result-
ing in difficult-to-treat infections. Farm wastewater con-
taminated with fecal matter harboring resistant pathogens
can accumulate as runoff in nearby rivers, streams, and
ground water.48 These resistant pathogens can exchange
DNA with the existing organisms of that environment
and cause life-threatening bacterial infections in human
hosts downstream.49 Manure from treated animals used
for fertilization results in the selection for increased antibi-
otic resistance in soil microorganisms, which are ultimately
transferred to the crop at harvest and then on to
consumers.48,50,51
Establishment of environmental reservoirs
In many parts of the world, over-the-counter sales resulting
in inappropriate and/or excessive use, payback mecha-
nisms, and lack of oversight plague antibiotic production.52
A related concern is the potential for the release of drug-
8 Experimental Biology and Medicine
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containing effluent from pharmaceutical manufacturing
centers into the environment, resulting in selection pres-
sure that facilitates the evolution of antibiotic resistance.
For example, an LC-MS analysis of samples from 28 differ-
ent sites around a bulk drug producing area in Hyderabad,
South India, resulted in the identification of high
concentrations of three antimicrobials (and increased con-
centrations of eight others) from each site. Further, tandem
microbiological studies found the presence of extended-
spectrum b-lactamase (ESBL) and carbapenemase-
producing Enterobacteriaceae and non-fermenters in 95% of
the samples.53 The release of drugs into the environment
has global consequences in terms of increasing the potential
for infections by pathogens that are resistant to the very
antimicrobials that we are producing on an industrial scale.
Mechanisms of antibiotic resistance
Antibiotic resistance is a natural phenomenon that predates
the discovery of antibiotics and the selective pressures of
antibiotic use, as genes providing resistance to the b-lactam,
tetracycline, and glycopeptide antibiotics have been identi-
fied from 30,000-year-old Beringian permafrost sedi-
ments.54 This natural resistance can be a direct result of
competition between microorganisms in the environment
but can also stem from spontaneous mutations that confer
an adaptive benefit.55 The dissemination of resistance can
occur horizontally, carried between species via mobile
genetic elements such as prophages, conjugative plasmids,
or insertion sequences.56 It can also be inherited vertically
by genetic mutations that are subsequently propagated in
each daughter cell.57 Bacteria can be resistant to certain
antibiotics by virtue of their physiology as well. For
instance, the low permeability barrier of the Gram-
negative outer membrane (Figure 1(a)) serves as the first
line of defense and provides intrinsic resistance to many
antibiotics.58 As an example, Gram-negative bacteria are
not susceptible to daptomycin, likely due to a lower abun-
dance of anionic phospholipids that are required for the
Ca2þ-mediated insertion of the lipopeptide antibiotic.59
Thus, daptomycin is limited to the treatment of Gram-
positive organisms (Figure 1(b)). The widespread use of
antibiotics is thought to have provided the selective pres-
sure to accelerate development of antibiotic resistance and
MDR in previously susceptible clinically-relevant microor-
ganisms.60 Acquired resistance to essentially all antibiotics
can be achieved by genetic mutations, the acquisition of
genes or modulation of gene expression, and new resis-
tance mechanisms continue to be characterized.61,62
Generally, these mechanisms include lowering the antibiot-
ic concentration in the cell (either by reducing entry or
increasing efflux63), protecting the target or altering the
target structure (through mutations, enzymatic modifica-
tions, or protein binding64), over-expression of the
target65 or modifications to inactivate the antibiotic66
(Figure 1(c)). Resistance can also be due to multiple mech-
anisms that are not mutually exclusive. In addition to target
mutations, other mutations that result in reduced drug
accumulation by either increased efflux or decreased
uptake, as well as horizontal transmission by plasmids
carrying genes for target protection proteins or drug mod-
ifying enzymes can give rise to resistance.67
Porins
Hydrophilic antibiotics (such as the b-lactams) can cross
Gram-negative and mycobacterial membranes through
aqueous channels called porins that normally provide the
organism with nutrients.63 Porins are classified according
to their structure, selectivity and expression regulation.
Antibiotic uptake can be decreased by altering the type or
level of porin expression or altering the selectivity/function
of these channels.61,62 As an example, studies of Klebsiella
pneumoniae clinical isolates revealed that porin integrity
was more of a determinant for carbapenem resistance
than the presence of ESBL.68 The study did not detect car-
bapenemases among 61 Chilean clinical isolates of
carbapenem-resistant Enterobacteriaceae, so resistance was
attributed to a combination of porin loss or alteration and
b-lactamase activity. Another study characterized clinical
isolates of Enterobacter aerogenes from patients treated
with the carbapenem drug imipenem and linked altered
porin expression with the adaptive response of E. aerogenes
to the antibiotic.69
Efflux pumps
While alterations to porins can reduce the penetration of
antibiotics, efflux pumps actively transport many antibiot-
ics out of Gram-negative and Gram-positive organisms.70
Among the first efflux pumps to be described was the
system that pumps tetracyclines out of E. coli.71 The efflux
pumps can have a narrow or broad range of specificity for
antibiotic substrates and increased expression can enable
higher levels of resistance to an antibiotic. Pumps able to
transport different classes of antibiotics are associated with
MDR. The five major families of efflux pumps include the
ATP-binding cassette (ABC) superfamily, the major facilita-
tor superfamily (MFS), the multidrug and toxic-compound
extrusion (MATE) family, the small multidrug-resistance
(SMR) family, and the resistance nodulation division
(RND) family.70 Classification into a family is based on
the number of components comprising the pump, the
number of transmembrane-spanning regions, the energy
source for active transport and the substrate type. The
efflux transporters with the highest clinical relevance
from Gram-positive bacteria are members of the MFS,
whereas for Gram-negative organisms the transporters
are from the RND family, which are able to extrude a
wide range of antibiotics.70 Recently, genomic analysis of
pre- and post-therapy MDR clinical isolates of Salmonella
typhimuriumwere compared from a patient that failed anti-
bacterial therapy and a G288D mutation was identified in
the Naþ regulatory domain (NRD) transporter acriflavine
resistance protein (AcrB) of the AcrAB-TolC tripartite MDR
efflux pump system.72 Characterization studies indicated
that the mutation increased the efflux of the fluoroquino-
lone antibiotic ciprofloxacin but decreased the efflux of
other drugs. While this study demonstrates how mutations
to a transporter can alter bacterial susceptibility to antibi-
otic therapy, mutations can also alter the regulatory
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network controlling the expression of efflux pumps to
result in increased antibiotic resistance.62 Resistance to anti-
biotics has also been linked to a combination of efflux pump
overexpression and porin downregulation in clinical iso-
lates from Pseudomonas aeruginosa, K. pneumoniae, and E.
coli.73,74
Protecting the target
A general strategy to achieve antibiotic resistance is to pre-
vent an antibiotic from binding its target, which can be
accomplished by different means. One paradigm of this is
a target-protection mechanism, whereby a protein can asso-
ciate with the drug target to prevent association with the
antibiotic. An example is given by the FusB fusidic acid
resistance protein, which protects elongation factor G
(EF-G) from the antibiotic fusidic acid (FA). FA is a steroid
antibiotic that is effective against Gram-positive bacteria,
including MRSA, and acts by inhibiting the release of EF-
G from the ribosome, thereby halting protein synthesis and
inducing growth arrest.75 Recent structural studies of the
FusB-EF-G complex by solution NMR revealed dynamic
changes in EF-G following FusB binding that facilitates dis-
assembly of the stalled post-translational complex to rescue
protein synthesis.76 Another mechanism to prevent target
engagement by an antibiotic is genetic mutations to the
target gene. An example of this is fluoroquinolone resis-
tance, which can result from mutations to DNA gyrase
and topoisomerase IV that are targets of the antibiotic.77
Mutations to the topoisomerases alter their structures to
reduce the binding efficiency of quinolones.
Altering the target structure
Alternatively, modifications to antibiotic target structures
can be achieved enzymatically. For example, the
chloramphenicol-florfenicol resistance (Cfr) ribosomal
RNA (rRNA) methyltransferase of Gram-positive and
Gram-negative bacteria modifies the 23S rRNA at position
A2503, providing MDR to a range of antibiotics including:
phenicols, lincosamides, oxazolidinones, pleuromutilins,
and streptogramin A.78
Altered gene expression
Resistance to antibiotics can be due to the modulation of
gene expression. For example, resistance to methicillin in S.
aureus results from the mecA gene that encodes PBP2a, a
PBP that has low affinity for many b-lactams including
penicillins, cephalosporins, and carbapenems.79 While
this is an example of replacing a target with another protein
of similar biochemical function that is not susceptible to
antibiotics, resistance has also been achieved by overex-
pression of a target to a concentration beyond what the
antibiotic can inhibit. For instance, a clinically isolated
strain of E. coli was shown to have mutations that resulted
in overexpression of dihydrofolate reductase by several
hundredfold, which resulted in a three-fold increase in
the Ki for the antifolate drug trimethoprim.
80
Modifications to the antibiotic
Antibiotic resistance can also be achieved through bio-
chemical modifications to the antibiotic, including hydro-
lysis, group transfer, and redox mechanisms.66 The
b-lactamase enzymes provide a classic example of a hydro-
lysis mechanism, as the first b-lactamase termed
“penicillinase” was identified in, 1940 from E. coli prior to
the clinical use of penicillin.81,82 Since that time, more than
850 b-lactamases have been identified, which are able to
hydrolyze b-lactam antibiotics (including penicillins, ceph-
alosporins, monobactams, and carbapenems).83
Alternatively, antibiotics can be inactivated due to various
chemical modifications, including acylation, phosphoryla-
tion, glycosylation, nucleotidylation, ribosylation, and thiol
transfer.66 For example, the aminoglycoside antibiotic kana-
mycin B can be enzymatically modified by acylation, phos-
phorylation, and nucleotidylation.84 A well-studied
example of the redox mechanism of antibiotic inactivation
is the enzyme TetX, which catalyzes the monohydroxyla-
tion of tetracyclines at position 11a, disrupting the antibi-
otic Mg2þ-binding site which is required for antibacterial
activity.66
From a perspective of evolving drug resistance, it is
interesting to consider how the structures of approved anti-
biotics have changed over time. Fifty-nine b-lactam drugs
were approved by the FDA between 1947 and 2014 (Table
1). To capture the evolution of these molecules since peni-
cillin G was approved, structural similarities were evaluat-
ed among all 59 b-lactam drugs. The method of maximal
common substructure (MCS) clustering was applied to
detect various chemotypes through the identification of
common structural elements among similar molecules.85,86
The expected outcome from such an analysis is that mole-
cules in a given cluster are more similar to each other than
to molecules of another cluster. The resulting chemical
space–time analysis is shown in Figure 3. The 2-dimension-
al transformation reveals closely related molecules and the
overall structural diversity among the b-lactam antibacte-
rial drugs. To highlight the evolution of b-lactam chemo-
types, selected structures are shown. The plot clearly shows
a trend towards new scaffolds over the course of time.
New approaches for small molecule
antimicrobials
Due to the crisis of antibiotic resistance, it is necessary to
explore alternate or adjunctive therapies to enhance our
current defenses against infectious diseases. Analyzing
the role of small molecules to advance our strategies against
antibiotic-tolerant and -resistant bacterial infections is of
great interest and has afforded a number of successful
new approaches.
New chemotypes
As indicated in the previous section, the development of
resistance against new antibiotics by pathogenic organisms
is essentially inevitable due to a range of mechanisms.
However, resistance is not anticipated to be easily devel-
oped against the recently discovered antibacterial molecule
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pseudouridimycin (PUM), which is a nucleoside analog.88
Because PUM binds directly and specifically to the
nucleotriphosphate-binding active site of bacterial RNA
polymerase (RNAP), mutations that reduce PUM binding
would likely also reduce or abolish enzymatic activity. The
compoundwas identified from extracts of soil microbes in a
screen for inhibitors of bacterial RNAP. PUM inhibited
Gram-negative and Gram-positive bacterial growth,
including drug resistant Streptococcus strains, at low micro-
molar concentrations and cleared infection in a mouse
model of Streptococcus pyogenes peritonitis. The antibiotic
rifampin binds RNAP at a distinct site and additive anti-
bacterial activity was observed when PUM and rifampin
were co-administered.88
New chemotypes are required to stay ahead of the
rapid evolution of antibiotic resistance. The fatty acid bio-
synthesis type 1 enzyme (FabI) has been known as an
antibacterial target for many years, but several new inhib-
itors are currently in clinical development that appear to
offer genuinely new chemotypes, including afabicin
(Deniopharm International), and CG400549
(CrystalGenomics), both of which are in phase II clinical
trials.89 As well, the mycolic acid transporter MmpL3 in
Mycobacterium tuberculosis has been targeted by novel
diamine- and indolamide-based compounds, and these
have been determined to be synergistic or additive with
the activity of other antimicrobials, increasing their utility
and effectiveness.90
Chemotypes for broad-spectrum activity
A recent advancement in the understanding of ideal phys-
icochemical properties for small molecule antibacterials
was made by Richter and colleagues, who studied a diverse
set of compounds and used structure–activity relationship
studies with computational analyses to develop predictive
guidelines for small molecule accumulation in Gram-
negative bacteria.91 Notably, the results indicated that
small molecules most likely to accumulate contain an
amine, are both rigid and amphiphilic and have low glob-
ularity, which differed substantially from the properties
thought to be important based on a retrospective analysis
of known antibiotics, particularly polarity and molecular
weight. The authors note that compounds with primary
amines are rare in standard compound libraries used for
high-throughput screening and the assembly of compound
collections that meet the guidelines for accumulation might
enable the discovery of novel chemical leads for the devel-
opment of broad-spectrum antibiotics.
New targets
A potential target for new antibiotics is the membrane
enzyme phospho-MurNAc-pentapeptide translocase
(MraY), which is essential for the synthesis of the bacterial
envelope. The role of MraY is to catalyze the initial process-
es in peptidoglycan synthesis by generating uridine-
monophosphate (UMP) and lipid 1. There are MraY
Figure 3. Chemical space-time of b-lactam antibacterial drugs. The dots indicate structures of b-lactam antibacterial drugs in a 2-dimensional chemical space. The
distance between dots reflects the extent of structural similarity, with similar structures in closer proximity. The color and size of the dots corresponds to the year of
FDA-approval, with more recent approvals indicated by a color closer to the blue end of the spectrum and a smaller size. The maximal common substructure (MSC)
clustering was performed with a similarity threshold of 0.60 using the StarDrop scientific software suite (version: 6.2.0, Optibrum Ltd, Cambridge, UK). The clustering
resulted in 11 MCS clusters and eight singletons (Table 1). In oder to characterize the diversity among b-lactam structures, they were embedded in a 2-dimensional
space using the t-distributed stochastic neighbor embedding algorithm of StarDrop.,87
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inhibitors currently in development, but some issues
remain, not the least of which is the challenge of bacterial
cell entry and the problem of the inhibitor reaching effec-
tive levels within the cell.9
Riboswitches, which are segments of mRNA that can
bind to small molecules and metabolites, are also potential
targets for antimicrobial molecules. Engineered small mol-
ecules can inhibit the function of riboswitches and some
were shown to be effective in bacteria. Ribocil is a selective
chemical modulator that binds to riboflavin riboswitches
and prevents riboflavin production in bacteria. The use
of ribocil was shown to lower the E. coli bacterial burden
in a mouse model of septicemia by two to three orders of
magnitude.92 While further research on riboswitches as
drug targets is warranted, caveats include the potential
for gain of mutations as well as the observed difficulty for
some modulators to cross the bacterial cell wall.
Nevertheless, these molecules represent unique targets
and an opportunity for novel antimicrobials.93
A promising approach for new antibacterials is antivir-
ulence, which focuses on targeting pathogenic bacteria by
binding to and inhibiting virulence factors such as toxins,
particularly those with enzymatic activity.94,95 For example,
a small molecule was identified in silico and confirmed in
vitro and in vivo to target the enzymatic site of Shiga toxin
from Shigella dysenteriae.96 In theory, because these viru-
lence factors are not necessary for bacterial survival outside
the context of a host infection, this approach will not apply
direct selective pressure and therefore resistance should not
rapidly emerge. Antivirulence treatments are anticipated to
supplement small molecule therapeutics and improve their
efficacies, resulting in optimal clinical treatment regimens.
Drug repurposing
The approval of new antibiotics has declined during
the past three decades (Figure 2) while resistance to the
approved antibiotics continues to increase. Despite an
urgent need for new antibiotics, most major pharmaceutical
companies have moved away from the antibacterial market
thereby drying up the pipeline for new treatments.2
Therefore, repurposing of approved drugs to treat infec-
tious diseases might provide an alternative approach for
effective new therapies.98 Approved drugs repurposed
for a new indication can be rapidly advanced to phase II
clinical trials without a phase I clinical trial due to the exist-
ing preclinical, human pharmacokinetics, and drug safety
data. An example of repurposing a drug to treat bacterial
infections is provided by the gold-containing compound
auranofin. This drug is FDA-approved for the treatment
of rheumatoid arthritis, but has also demonstrated antimi-
crobial activity against a range of Gram-positive and Gram-
negative pathogens.98–105 The thiol ligand of auranofin can
form irreversible adducts with selenol or thiol groups, and
auranofin is a well-known inhibitor of reduction/oxidation
enzymes including thioredoxin reductase (TrxR).98
The antibacterial activity of auranofin has been linked to
the disruption of selenium metabolism and interference
with a number of selenoproteins including glycine reduc-
tase, proline reductase, and xanthine dehydrogenase.99–101
Biochemical studies have demonstrated that auranofin is a
potent inhibitor of bacterial TrxR, which is not targeted by
other antibiotics and is involved in a variety of processes
required for survival and proliferation, such as DNA syn-
thesis and protein repair.104 The ability of auranofin to
interfere with multiple bacterial enzymes might reduce
the development of resistance.
Synergistic combinations
Drug combinations have been approved for the treatment
of bacterial infections, such as the combination of amoxicil-
lin (a b-lactam) with clavulanic acid (a b-lactamase inhibi-
tor).106 Advantages of drug combinations include
extending the spectrum of susceptible organisms, overcom-
ing drug resistance, reducing the development of antibiotic
resistance, and the potential for drug synergies.97
New combinations of antibiotics have been successfully
applied to treat drug-resistant pathogens. For example, a
combination of three b-lactams (meropenem, piperacillin,
tazobactam) was reported to act synergistically against
MRSA and showed similar in vivo activity to the oxazolidi-
none antibiotic linezolid.107 While Gram-negative bacteria
are intrinsically resistant to the antibiotic vancomycin, a
study showed strong synergies against E. coli when com-
bining vancomycin with antibiotics such as trimethoprim
or nitrofurantoin.108 The drug fosfomycin, which has
been registered in the United States for oral treatment of
uncomplicated UTIs since 1995, has been tested as a partic-
ipant in a cocktail with polymyxin B, tobramycin or cipro-
floxacin to target P. aeruginosa, although issues with
resistance remain.109,110 Other novel combinations of anti-
biotics have shown synergy against Gram-negative patho-
gens, includingAcinetobacter baumannii.111 Progress has also
been made in identifying synergistic drug combinations
that combine antibiotics with approved drugs not previ-
ously used to treat infections. As an example, the antibiotic
penicillin G is primarily only active against Gram-positive
organisms, but showed synergistic activity with the non-
antibiotic drug promethazine against E. coli.112 The opioid
receptor agonist loperamide (Imodium) is an approved
anti-diarrheal that was shown to synergize with tetracy-
clines due to its ability to dissipate bacterial membrane
potential and enhance antibiotic uptake.113 Recently, a
drug combination screen identified 17 synergistic three-
drug combinations that were effective against K. pneumo-
niae at concentrations which are clinically achievable.
Additionally, three sets of three-drug combinations, two
of which contained auranofin, were active against a panel
of 10 MDR clinical isolates, including K. pneumoniae, A.
baumannii, P. aeruginosa, Citrobacter freundii, Enterobacter clo-
acae, and E. coli.105 While the previous examples of combi-
nations utilized antibiotics, an interesting strategy was
recently applied to completely replace an antibiotic pair
with non-antibiotic drugs. The aim was to identify syner-
gistic pairs based on the antibiotics trimethoprim and sul-
famethoxazole that have been used in combination for
decades to treat bacterial infections. First, the antiviral
drug azidothymidine (AZT) was found to synergize with
trimethoprim or sulfamethoxazole against MDR E. coli and
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K. pneumoniae. The development of a mechanistic under-
standing of the underlying interaction enabled the discov-
ery of synergy between AZT and the cancer drug
floxuridine, which reduced the median bacterial burden
by 10,000-fold compared with the traditional pair of tri-
methoprim/sulfamethoxazole in a zebrafish model.114
The potential opportunities to repurpose drugs,
although exciting, are not without challenges.115–117 There
are safety concerns associated with utilizing drugs known
to target host tissues, such as oncology medications.116
Additionally there are currently major economic barriers
to repurposing because there are insufficient market incen-
tives to advance drugs that are off-patent. It has been esti-
mated that repurposing a drug costs around $300 million
and takes about 6.5 years.117 Other current challenges
include intellectual property rights and other legal
concerns, regulatory issues and timelines, return on invest-
ment, as well as the design and execution of proof-of-
concept clinical trials.
Financial concerns
Another unsolved but important issue in the search for
effective small molecule antibiotics is that of return on
investment. Most pharmaceutical companies are in busi-
ness to make a profit for their shareholders, and antimicro-
bial drug discovery is currently not profitable. It was
recently estimated that the cost of a new drug with
market approval is $2.6 billion and takes more than a
decade to develop.118 When a new antibiotic is finally avail-
able to the public, it is prescribed only transiently for infec-
tions and not needed by otherwise healthy people on a
regular basis, unlike medications that lower cholesterol or
treat high blood pressure. To address these concerns and
incentivize antibacterial drug development, in 2012 the
112th United States Congress passed the Food and Drug
Administration Safety and Innovation Act,119 which
included as Title VIII the “Generating Antibiotic
Incentives Now” (GAIN) Act. As a commercial induce-
ment, the GAIN Act extended the market exclusivity
period, which is the length of time that a pharmaceutical
company is allowed to be the sole provider of an antimi-
crobial by law. At the same time, an FDA Task Force was
launched to identify challenges and provide guidance for
antibiotic drug resistance.
A novel solution to this problem has been put forward
which consists of incentivizing antibacterial research and
development by drug companies using a model that is
either fully or partially delinked from drug sales through
milestone payments and other financial encourage-
ments.120 The successful implementation of this model
would require both multinational coordination and coop-
eration as well as regional and global banking institutional
support. However, because the health threat posed by
antibiotic-resistant organisms affects the population world-
wide, this approachmight have merit and should be subject
to serious consideration.
Conclusions
It is not an exaggeration to describe our current situation as
an evolutionary “arms race” against antibiotic-resistant
microorganisms. There is not likely to be a single com-
pound or class of drugs that will continue to be effective
for the foreseeable future against bacterial infections.
Rather, the prediction is that we will discover novel treat-
ments (natural, man-made or new combinations) that will
initially be valuable additions to our arsenal of antibiotics,
but which will eventually lose efficacy due to bacterial
resistance mechanisms. This is a clear indication that aca-
demia, industry and government must be called upon to
invest in a concerted and unified effort to fill the drug
development pipeline with new antimicrobials. The first
antibiotic was released to the public more than 80 years
ago, which means that there are people alive today that
were born in the pre-antibiotic era. For those of us that
were raised in a world with available and effective treat-
ments, imagining a future without antibiotics is daunting
indeed.
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